Cash and cash equivalents as of March 31, 2025, were $17.8 million, as compared to $6.0 million as of December 31, 2024. The significant improvement in our cash position is due to our successful capital markets initiatives in January 2025, and we expect our existing cash and cash equivalents to be sufficient to fund our operating expenses and capital expenditure requirements until mid-2026.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EVAX:
- Evaxion A/S to Announce Q1 2025 Financial Results and Business Update
- Evaxion Begins Extension of Phase 2 Trial for AI-Designed Cancer Vaccine
- Evaxion Biotech doses first patient in extension of phase 2 trial on EVX-01
- Evaxion Biotech A/S Announces Key Resolutions from April 2025 AGM
- Evaxion Biotech Updates Warrant Terms and Subscription Prices
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue